Drug Profile
Budesonide controlled-release - Cosmo Pharmaceuticals
Alternative Names: Budesonide controlled release; Budesonide CR; Budesonide MMX®; budesonide multimatrix; Cortiment; Cortiment MMX; FE 999315; Uceris oralLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Cosmo Pharmaceuticals
- Developer Cosmo Pharmaceuticals; Ferring Pharmaceuticals; Salix Pharmaceuticals
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ulcerative colitis
Most Recent Events
- 28 Jun 2023 Registered for Ulcerative colitis (In adolescents, In the elderly, In adults) in Japan (PO)
- 28 Jun 2023 Ferring Pharmaceuticals announces intention to initiate first sales of budesonide controlled-release (Cortiment®) for Ulcerative colitis in Japan (PO) by the end of Q3 2023
- 19 Aug 2022 Pharmaceuticals and Medical Devices Agency (PMDA) has accepted NDA application for review